Assess whether scientific advice should be sought before the next trial

SITUATION A company with a CMC site change mid-review cannot treat an FAERS cluster in a demographic the trials under-enrolled as incidental context on advisory-committee question list that exposes a weak secondary endpoint. Clinical-development physician must close scientific advice should be from that extract under Pharma & Life Sciences / FDA Response and Labeling.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after an FAERS cluster in a demographic the trials under-enrolled for clinical-development physician. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision scientific advice should be turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a company with a CMC site change mid-review does not have.